STAAR Surgical Company (NASDAQ:STAA) was more active in the last trading session as around 0.27 million shares exchanged hands on Wall Street, representing an increase from its normal capacity of 0.13 million shares. A 4.19% change after the initial price of $16.6, sent the closing price to $17.4.

STAAR Surgical Company (STAA) Analyst Opinion

STAAR Surgical Company has a consensus outperform rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 3.73% of shares outstanding. The stock spiked 32.32% last month and is up 60.37 this year. Wall Street is only getting more bullish on the stock, with 3 of analysts who cover STAA having a buy-equivalent rating. Analysts have placed a $18.5 price target on STAAR Surgical Company, suggesting a 6.32% gain from recent close. It’s currently trading about 3.88% above its 52-week high.

STAAR Surgical Company Earnings Surprise

STAAR Surgical Company (STAA) surprised the stock market in its last reported earnings when it earned $0.03 a piece versus the consensus-estimated -$0.04. Its revenue totaled $21.45 million down -2.23% from the previous quarter.

STAAR Surgical Company (NASDAQ:STAA) Intraday View

This stock (STAA) is ahead of its 52-week low with 94.41%. Its last month’s stock price volatility remained 3.33% which for the week stands at 4.48%. The share price has moved forward from its 20 days moving average, trading at a distance of 15.94% and stays 27.35% away from its 50 days moving average. Over the last five days, shares have managed 4.19% gains and now is up 56.64% since hitting its 200-day moving average of $11.68. STAAR Surgical Company (STAA) has made its way to a 12-month gain of 61.86%.

Turning to Five Prime Therapeutics, Inc. (NASDAQ:FPRX), its shares were trading at $25.55 a retreat of $-1.26, on the trading floor. The stock, after opening at $26.82, touched a high of $26.97 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.4. Five Prime Therapeutics, Inc. has 5 buy ratings, 0 holds and 0 sells even after the stock tumbled -57.23% from its high of $59.74 to a $738.14 million market value through last close.

Five Prime Therapeutics, Inc. (FPRX) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.44 to 1.44 during a month. Analysts set a 12-month price target of $63.06 a share. The target implies a 146.81% spike from where the shares are currently trading. Also, the current price highlights a discount of 267.91% to analysts’ high consensus price target.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Intraday Trading

The counter witnessed a trading volume of 0.65 million shares versus an average volume of 0.55 million shares during last trading session. Its last month’s stock price volatility remained 3.38% which for the week approaches 10.4%. The lowest price the stock reached in the last trading day was $25.37 and compares with the $21.41 52-week low. The stock recovered 19.34% since its low point and has performed -49.01% year-to-date.